PMID- 31300285
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20211113
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 37
IP  - 35
DP  - 2019 Aug 14
TI  - Effective mosaic-based nanovaccines against avian influenza in poultry.
PG  - 5051-5058
LID - S0264-410X(19)30854-0 [pii]
LID - 10.1016/j.vaccine.2019.06.077 [doi]
AB  - Avian influenza virus (AIV) is an extraordinarily diverse pathogen that causes 
      significant morbidity in domesticated poultry populations and threatens human 
      life with looming pandemic potential. Controlling avian influenza in susceptible 
      populations requires highly effective, economical and broadly reactive vaccines. 
      Several AIV vaccines have proven insufficient despite their wide use, and better 
      technologies are needed to improve their immunogenicity and broaden 
      effectiveness. Previously, we developed a "mosaic" H5 subtype hemagglutinin (HA) 
      AIV vaccine and demonstrated its broad protection against diverse highly 
      pathogenic H5N1 and seasonal H1N1 virus strains in mouse and non-human primate 
      models. There is a significant interest in developing effective and safe vaccines 
      against AIV that cannot contribute to the emergence of new strains of the virus 
      once circulating in poultry. Here, we report on the development of an H5 mosaic 
      (H5M) vaccine antigen formulated with polyanhydride nanoparticles (PAN) that 
      provide sustained release of encapsulated antigens. H5M vaccine constructs were 
      immunogenic whether delivered by the modified virus Ankara (MVA) strain or 
      encapsulated within PAN. Both humoral and cellular immune responses were 
      generated in both specific-pathogen free (SPF) and commercial chicks. 
      Importantly, chicks vaccinated by H5M constructs were protected in terms of viral 
      shedding from divergent challenge with a low pathogenicity avian influenza (LPAI) 
      strain at 8 weeks post-vaccination. In addition, protective levels of humoral 
      immunity were generated against highly pathogenic avian influenza (HPAI) of the 
      similar H5N1 and genetically dissimilar H5N2 viruses. Overall, the developed 
      platform technologies (MVA vector and PAN encapsulation) were safe and provided 
      high levels of sustained protection against AIV in chickens. Such approaches 
      could be used to design more efficacious vaccines against other important poultry 
      infections.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Kingstad-Bakke, Brock A
AU  - Kingstad-Bakke BA
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA; Pan Genome Systems, Madison, WI, USA.
FAU - Chandrasekar, Shaswath S
AU  - Chandrasekar SS
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA.
FAU - Phanse, Yashdeep
AU  - Phanse Y
AD  - Pan Genome Systems, Madison, WI, USA.
FAU - Ross, Kathleen A
AU  - Ross KA
AD  - Department of Chemical and Biological Engineering, Iowa State University, Ames, 
      IA, USA.
FAU - Hatta, Masato
AU  - Hatta M
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA.
FAU - Suresh, M
AU  - Suresh M
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA.
FAU - Kawaoka, Yoshihiro
AU  - Kawaoka Y
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA.
FAU - Osorio, Jorge E
AU  - Osorio JE
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA.
FAU - Narasimhan, Balaji
AU  - Narasimhan B
AD  - Department of Chemical and Biological Engineering, Iowa State University, Ames, 
      IA, USA.
FAU - Talaat, Adel M
AU  - Talaat AM
AD  - Department of Pathobiological Sciences, School of Veterinary Medicine, University 
      of Wisconsin, Madison, WI, USA; Pan Genome Systems, Madison, WI, USA. Electronic 
      address: adel.talaat@wisc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20190709
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hemagglutinin Glycoproteins, Influenza Virus)
RN  - 0 (Influenza Vaccines)
RN  - 0 (hemagglutinin, avian influenza A virus)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/*blood
MH  - Chickens/immunology
MH  - Hemagglutinin Glycoproteins, Influenza Virus/chemistry/immunology
MH  - Immunity, Cellular
MH  - Immunity, Humoral
MH  - Influenza A Virus, H1N1 Subtype
MH  - Influenza A Virus, H5N1 Subtype
MH  - Influenza A Virus, H5N2 Subtype
MH  - Influenza Vaccines/administration & dosage/*immunology
MH  - Influenza in Birds/*prevention & control
MH  - Nanoparticles/*administration & dosage/chemistry
MH  - Vaccination/*veterinary
OTO - NOTNLM
OT  - Avian influenza
OT  - Modified vaccinia Ankara
OT  - Nanoparticle vaccine
OT  - Vaccine vector
EDAT- 2019/07/14 06:00
MHDA- 2020/10/07 06:00
CRDT- 2019/07/14 06:00
PHST- 2019/02/14 00:00 [received]
PHST- 2019/05/15 00:00 [revised]
PHST- 2019/06/24 00:00 [accepted]
PHST- 2019/07/14 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2019/07/14 06:00 [entrez]
AID - S0264-410X(19)30854-0 [pii]
AID - 10.1016/j.vaccine.2019.06.077 [doi]
PST - ppublish
SO  - Vaccine. 2019 Aug 14;37(35):5051-5058. doi: 10.1016/j.vaccine.2019.06.077. Epub 
      2019 Jul 9.